FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2890203489> ?p ?o ?g. }

• W2890203489 endingPage "1918" @default.
• W2890203489 startingPage "1906" @default.
• W2890203489 abstract "IntroductionCancer immunotherapy may alter tumor biology such that treatment effects can extend beyond radiographic progression. In the randomized, phase III OAK study of atezolizumab (anti–programmed death-ligand 1) versus docetaxel in advanced NSCLC, overall survival (OS) benefit with atezolizumab was observed in the overall patient population, without improvement in objective response rate (ORR) or progression-free survival (PFS). We examine the benefit-risk of atezolizumab treatment beyond progression (TBP).MethodsEight hundred fifty patients included in the OAK primary efficacy analysis were evaluated. Atezolizumab was continued until loss of clinical benefit. Docetaxel was administered until Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1) disease progression (PD)/unacceptable toxicity; no crossover to atezolizumab was allowed. ORR, PFS, post-PD OS, target lesion change, and safety were evaluated.ResultsIn atezolizumab-arm patients, ORR was 16% versus 14% and median PFS was 4.2 versus 2.8 months per immune-modified RECIST versus RECIST v1.1. The median post-PD OS was 12.7 months (95% confidence interval [CI]: 9.3–14.9) in 168 atezolizumab-arm patients continuing TBP, 8.8 months (95% CI: 6.0–12.1) in 94 patients switching to nonprotocol therapy, and 2.2 months (95% CI: 1.9–3.4) in 70 patients receiving no further therapy. Of the atezolizumab TBP patients, 7% achieved a post-progression response in target lesions and 49% had stable target lesions. Atezolizumab TBP was not associated with increased safety risks.ConclusionsWithin the limitations of this retrospective analysis, the post-PD efficacy and safety data from OAK are consistent with a positive benefit-risk profile of atezolizumab TBP in patients performing well clinically at the time of PD." @default.
• W2890203489 created "2018-09-27" @default.
• W2890203489 creator A5003502388 @default.
• W2890203489 creator A5005127397 @default.
• W2890203489 creator A5014364032 @default.
• W2890203489 creator A5021274325 @default.
• W2890203489 creator A5025985477 @default.
• W2890203489 creator A5026119562 @default.
• W2890203489 creator A5030107272 @default.
• W2890203489 creator A5036091074 @default.
• W2890203489 creator A5042546997 @default.
• W2890203489 creator A5043917346 @default.
• W2890203489 creator A5044266059 @default.
• W2890203489 creator A5046304194 @default.
• W2890203489 creator A5055246540 @default.
• W2890203489 creator A5055776119 @default.
• W2890203489 creator A5056975051 @default.
• W2890203489 creator A5072196458 @default.
• W2890203489 creator A5072665111 @default.
• W2890203489 creator A5074479466 @default.
• W2890203489 creator A5078389632 @default.
• W2890203489 creator A5087836238 @default.
• W2890203489 date "2018-12-01" @default.
• W2890203489 modified "2023-10-11" @default.
• W2890203489 title "Atezolizumab Treatment Beyond Progression in Advanced NSCLC: Results From the Randomized, Phase III OAK Study" @default.
• W2890203489 cites W1971208896 @default.
• W2890203489 cites W2028376975 @default.
• W2890203489 cites W2087186136 @default.
• W2890203489 cites W2096734361 @default.
• W2890203489 cites W2100158834 @default.
• W2890203489 cites W2104347254 @default.
• W2890203489 cites W2122495232 @default.
• W2890203489 cites W2124427232 @default.
• W2890203489 cites W2140980839 @default.
• W2890203489 cites W2148706732 @default.
• W2890203489 cites W2151337547 @default.
• W2890203489 cites W2156353875 @default.
• W2890203489 cites W2166396356 @default.
• W2890203489 cites W2166478326 @default.
• W2890203489 cites W2167422856 @default.
• W2890203489 cites W2170962009 @default.
• W2890203489 cites W2198093519 @default.
• W2890203489 cites W2221045931 @default.
• W2890203489 cites W2222086386 @default.
• W2890203489 cites W2293531514 @default.
• W2890203489 cites W2386935098 @default.
• W2890203489 cites W2567564314 @default.
• W2890203489 cites W2586493371 @default.
• W2890203489 cites W2592144107 @default.
• W2890203489 cites W2725298133 @default.
• W2890203489 cites W2731198447 @default.
• W2890203489 cites W2752793362 @default.
• W2890203489 cites W2783708539 @default.
• W2890203489 cites W2784235889 @default.
• W2890203489 cites W2891723820 @default.
• W2890203489 cites W4250888037 @default.
• W2890203489 doi "https://doi.org/10.1016/j.jtho.2018.08.2027" @default.
• W2890203489 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30217492" @default.
• W2890203489 hasPublicationYear "2018" @default.
• W2890203489 type Work @default.
• W2890203489 sameAs 2890203489 @default.
• W2890203489 citedByCount "83" @default.
• W2890203489 countsByYear W28902034892019 @default.
• W2890203489 countsByYear W28902034892020 @default.
• W2890203489 countsByYear W28902034892021 @default.
• W2890203489 countsByYear W28902034892022 @default.
• W2890203489 countsByYear W28902034892023 @default.
• W2890203489 crossrefType "journal-article" @default.
• W2890203489 hasAuthorship W2890203489A5003502388 @default.
• W2890203489 hasAuthorship W2890203489A5005127397 @default.
• W2890203489 hasAuthorship W2890203489A5014364032 @default.
• W2890203489 hasAuthorship W2890203489A5021274325 @default.
• W2890203489 hasAuthorship W2890203489A5025985477 @default.
• W2890203489 hasAuthorship W2890203489A5026119562 @default.
• W2890203489 hasAuthorship W2890203489A5030107272 @default.
• W2890203489 hasAuthorship W2890203489A5036091074 @default.
• W2890203489 hasAuthorship W2890203489A5042546997 @default.
• W2890203489 hasAuthorship W2890203489A5043917346 @default.
• W2890203489 hasAuthorship W2890203489A5044266059 @default.
• W2890203489 hasAuthorship W2890203489A5046304194 @default.
• W2890203489 hasAuthorship W2890203489A5055246540 @default.
• W2890203489 hasAuthorship W2890203489A5055776119 @default.
• W2890203489 hasAuthorship W2890203489A5056975051 @default.
• W2890203489 hasAuthorship W2890203489A5072196458 @default.
• W2890203489 hasAuthorship W2890203489A5072665111 @default.
• W2890203489 hasAuthorship W2890203489A5074479466 @default.
• W2890203489 hasAuthorship W2890203489A5078389632 @default.
• W2890203489 hasAuthorship W2890203489A5087836238 @default.
• W2890203489 hasBestOaLocation W28902034891 @default.
• W2890203489 hasConcept C121608353 @default.
• W2890203489 hasConcept C126322002 @default.
• W2890203489 hasConcept C141071460 @default.
• W2890203489 hasConcept C143998085 @default.
• W2890203489 hasConcept C197934379 @default.
• W2890203489 hasConcept C2775949291 @default.
• W2890203489 hasConcept C2776694085 @default.
• W2890203489 hasConcept C2777701055 @default.
• W2890203489 hasConcept C2778375690 @default.

• next